Abstract. The brain is a highly compartmentalized organ exceptionally susceptible to accumulation of metabolic errors. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of the elderly and is characterized by regional specificity of neural aberrations associated with higher cognitive functions. Aluminum (Al) is the most abundant neurotoxic metal on earth, widely bioavailable to humans and repeatedly shown to accumulate in AD-susceptible neuronal foci. In spite of this, the role of Al in AD has been heavily disputed based on the following claims: 1) bioavailable Al cannot enter the brain in sufficient amounts to cause damage, 2) excess Al is efficiently excreted from the body, and 3) Al accumulation in neurons is a consequence rather than a cause of neuronal loss. Research, however, reveals that: 1) very small amounts of Al are needed to produce neurotoxicity and this criterion is satisfied through dietary Al intake, 2) Al sequesters different transport mechanisms to actively traverse brain barriers, 3) incremental acquisition of small amounts of Al over a lifetime favors its selective accumulation in brain tissues, and 4) since 1911, experimental evidence has repeatedly demonstrated that chronic Al intoxication reproduces neuropathological hallmarks of AD. Misconceptions about Al bioavailability may have misled scientists regarding the significance of Al in the pathogenesis of AD. The hypothesis that Al significantly contributes to AD is built upon very solid experimental evidence and should not be dismissed. Immediate steps should be taken to lessen human exposure to Al, which may be the single most aggravating and avoidable factor related to AD.
INTRODUCTION
Alzheimer's disease (AD) is a progressive form of dementia of the elderly and the most prevalent neurodegenerative disease in the world [1] . It is characterized by regional specificity of neural aberrations associated with higher cognitive functions in the hippocampus and neocortex [2] [3] [4] [5] [6] [7] [8] [9] . Notably, such compartmentalized distribution of neural abnormalities is a main feature by which AD is distinguished from other forms of dementia, such as Huntington's, Parkinson's, and Wilson's diseases, which primarily involve neurological deficits affecting brainstem nuclei function [10] . Since its initial report in 1906, AD has reached global proportions and currently, it is one of the most burdensome and disabling health problems, affecting ∼24.3 million people [11] . More than 4.5 million new cases are diagnosed each year and it is predicted that by 2040 there will be 81.1 million people with AD [11] . A very small percentage of AD cases is inherited (familial AD, early onset of symptoms, <65 years), whilst >95% are idiopathic (late onset, >65 years) [1, 12, 13] , and although several causative agents have been proposed, none is unambiguously proved nor ruled out [1, 3, 12, [14] [15] [16] [17] [18] [19] [20] .
Depositions of amyloid ␤-protein precursor (A␤PP)-derived amyloid-␤ (A␤) fibrils, which form extracellular senile plaques (Fig. 1) , and aggregates of hyperphosphorylated microtubule-associated protein (MAP) tau, which combines to form paired helical filaments (PHFs) within neurons ( Fig. 2 [1, 12, 14] ), are principal histopathological markers of AD [1, 12, 14] . However, it is not clear what triggers senile plaques and neurofibrillary tangles (NFT) formation in the absence of predisposing genetic susceptibilities. Furthermore, none of the alternative hypotheses that have been suggested thus far, including: 1) oxidative stress [17, 21] , 2) dysregulation of calcium [12, 22, 23] and iron homeostasis [24] [25] [26] [27] , 3) deficits in microtubules (MTs [20] ), 4) deficits in neurotransmission and G-protein-coupled receptor (GPCR) signaling [3-5, 8, 28] , and 5) upregulation of neuroinflammatory signaling [16, 29] , are able to explain the regional A B Fig. 1 . Domain structure and processing of the A␤PP. Panel A depicts the overall structure and cleaving sites for ␣-, ␤-and ␥-secretases. A␤PP is a type 1 trans-membrane protein that undergoes differential processing by two mutually exclusive pathways. Cleavage by ␣-secretase yields a neuroprotective soluble s␣-A␤PP and precludes the formation of the amyloidogenic neurotoxic A␤ 1-40/1-42 species which are produced by the sequential cleavage of ␤-and ␥-secretase. There are several A␤PP isoforms: A␤PP 751 and A␤PP 770 are glial-specific, while A␤PP 695 is the predominant neuronal isoform [12] . Panel B shows two distinct mechanisms by which PLC regulates A␤PP processing: PKC-dependent and Ca 2+ dependent/PKC-independent (adapted from Buxbaum et al. [22] ). Both pathways favor the formation of the neuroprotective s␣-A␤PP at the expense of the amyloidogenic A␤ species. Al promotes amyloidosis as it antagonizes the neuroprotective s␣-A␤PP pathway, by inhibiting agonist-stimulated PIP 2 hydrolysis by PLC and the formation of second messengers DAG and IP 3 (for further details see Fig. 2 ). 
promotes GDP to GTP exchange and activation of receptorcoupled G q -proteins which activate PLC. Hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) by activated PLC yields two important signaling molecules: IP 3 and diacylglycerol (DAG). IP 3 stimulates release of Ca 2+ from the ER and the mitochondria, and DAG, in concert with Ca 2+ , activates protein kinase C (PKC). Ca 2+ and PKC work by two separate mechanisms to stimulate the non-amyloidogenic pathway of A␤PP processing by ␣-secretase, which results in production of the neuroprotective soluble A␤PP (s␣-A␤PP). PKC promotes the budding of A␤PP-containing secretory vesicles from the trans-Golgi network (TGN) and potentially targets ␣-secretase at the plasma membrane. Ca 2+ activates calmodulin (CaM) which regulates the activity of the Ca 2+ /Mg 2+ -ATPases responsible for extrusion of cytosolic Ca 2+ . 2) AC is activated by adrenergic receptor stimulation (A R ) and consequent activation of A R -coupled G s -protein via GDP to GTP exchange. Activated AC catalyzes ATP to form the second messenger cAMP which then activates protein kinase A (PKA). PKA phosphorylates microtubule-associated protein (MAP) tau on PKA-dependent serine residues. Hyperphosphorylated tau dissociates from the MTs and assembles into paired helical filament (PHF)-structures, main constituents of neurofibrillary tangles (NFT). Note that MAP tau has multiple phosphorylation sites but PKA-dependent serine phosphorylation is associated with increased formation of NFT in AD [225] . Al interferes with the PLC/IP 3 and AC/cAMP pathways in a biphasic manner, by negative and positive modulations (indicated ∅ and ⊕ respectively), and at multiple levels. By impairing M R stimulated PIP 2 hydrolysis Al may promote both amyloidosis and cholinergic dysfunction. Note that acetylcholine (ACh) is a central neurotransmitter critical for higher cognitive functions and a classical activator of M R receptors. Deficits in cholinergic signaling are a hallmark of AD and are reciprocated by Al. Conversely, by increasing cAMP, Al may induce the formation of NFTs. specificity of neuronal degeneration, nor account for the subtle and persistent changes which over time result in progressive neural deterioration. Nor can these factors encompass the diversity of histological and molecular abnormalities observed in AD. While it is irrefutable that all of the aforementioned may be contributing events in AD, they cannot be instigated in the absence of either genetic predispositions or environmental triggers. Moreover, identical twin studies show that in 60% of cases, AD affects only one twin (the rate is similar for both monozygotic and dizygotic twins [30] ), thus further underscoring the importance of environmental factors in the etiology of AD. Out of all bioavailable factors considered, aluminum (Al) is the only one that has been experimentally shown to trigger all major histopathological events associated with AD, at multiple levels (Table 1) . It is also the most controversial proposed instigator [15, [31] [32] [33] [34] [35] [36] . May promote amyloidosis by interfering with the muscarinic acetylcholine receptor-stimulated IP 3 /PLC-regulated production of the neuroprotective nonamyloidogenic s␣-A␤PP ( Fig. 2 [4, 8, 22, 241, 287, 288] ): as fluoroaluminate, blocks DAG/PKC-dependent budding of secretory vesicles containing A␤PP from the trans-Golgi network (TGN), thus inhibiting A␤PP redistribution towards the plasma membrane where it would undergo processing by ␣-secretase to produce s␣-A␤PP [289] may inhibit IP 3 /Ca 2+ -dependent production of s␣-A␤PP [22, 288] may inhibit PKC-dependent A␤PP cleavage by ␣-secretase [289, 290] Inhibits proteolytic degradation of A␤ by cathepsin D [291] There are many unresolved questions about Al bioavailability. This perhaps leads to erroneous conclusions regarding the significance of Al in the pathogenesis of AD. This review elucidates how: 1) the brain's inherent structural and functional heterogeneity provides a basis for differential susceptibility of specific cellular systems to Al neurotoxicity and 2) how Al's active sequestration of specific systemic transport mechanisms results in its compartmentalized distribution within the brain in a pattern that strongly implicates its role in AD. Special emphasis is given to Al's chemical and physical properties and their relevance to the etiology of AD.
ALUMINUM AND AD: WHY IS THERE A DEBATE?
Al, the third most abundant element on earth (after oxygen and silicon [37] [38] [39] [40] ), has been demonstrated in the literature to be a neurotoxin (Table 1) . It is widely bioavailable to humans (Tables 3-5 ) and known to accumulate at higher concentrations in brain regions that are selectively affected in AD, including the entorhinal cortex (an area that shows the earliest pathological changes in AD), hippocampus, and the amygdala [2, [41] [42] [43] [44] [45] [46] [47] [48] . Pyramidal cells in the hippocampus and cortex, basal forebrain cholinergic neurons, and upper brainstem catecholaminergic neurons associated with higher cognitive functions are the most affected neuronal populations in AD and also, the most susceptible to Al-induced neurofibrillary degeneration [10, 43, 47, 49, 50] . A strong association of Al with NFTs in AD was first observed by Perl and Brody [42] , who used a combination of scanning electron microscopy and X-ray spectrometry, which enabled them to assess the localization of Al in brain biopsies at cellular and subcellular levels. Al foci were explicitly found within the nuclear regions of NFTbearing neurons in the hippocampi from AD patients as well as non-demented elderly controls, while they were absent from adjacent healthy neurons from both groups of patients. Perl and Brody's observations were later confirmed by Andrasi et al. [51] using more sophisticated method (which eliminated the interfering reaction of phosphorous) and were also experimentally reproduced by Uemura [52] in an animal model of Al-induced neurofibrillary degeneration. Contrary to previous experiments, Uemura [52] was one of the first to examine the effects of chronic administration of Al in animals (administered subcutaneously over a period of either 40 or 90 days, rather than as a single intracerebral sub-lethal dose). Using a similar X-ray microprobe approach as Perl and Brody, Uemura [52] found elevated levels of Al within the nucleus of a high percentage of NFT-bearing neurons in the spinal cord and hippocampus. Also in concordance with Perl and Brody's results, Al was not detected in NFT-free neurons.
In spite of these observations, the causative role of Al in AD has been disputed, as some researchers failed to detect elevated levels of Al in AD brains despite using highly sophisticated and sensitive detection methods [53, 54] . These discrepancies fuelled further criticism about the Al-AD hypothesis and were further bolstered by the fact that Al has no biological essentiality, appears to be both poorly absorbed and efficiently excreted from the body [38] [39] [40] [55] [56] [57] and presumably, cannot accumulate in brain tissue in sufficient amounts to cause damage under physiologically relevant conditions [38, 40] . The presence of Al in the brain was subsequently attributed to experimental artifacts [54] or to passive uptake by dysfunctional neurons [58] . Furthermore, although Al-induced dialysis encephalopathy in chronic renal failure patients and intracerebral injection of a lethal threshold doses of Al in experimental animals results in development of neurofibrillary-like tangles, these lesions are less common and/or show distinct cellular topology and morphology from those in AD (although they are immunochemically similar to classical NFTs; Table 2 ). Similarly, the frequent occurrence of seizures, rapid progression, and severity of neuropathological abnormalities associated with Al-induced neurofibrillary degeneration in dialysis patients and experimental Table 2 Comparisons between AD, dialysis dementia and animal models of neurofibrillary degeneration and amyloidosis [82, 83] . In transgenic mice by 12 months [231] . Adult rats are generally maintained on an low Al-supplemented diet throughout life [2, 48, 61, 70, 82, 83] and mice for 12 months [231] Amyloid/senile plaques Common [1, 12-14, 16, 18] Detected in 30-50% of patients [44, 45] Uncommon Uncommon [2, 70, 82, 83, 231] typical extracellular senile plaques are species-specific and do not normally develop in rodents [70] but A␤PP accumulation is observed in affected dendrites and axons [70, 299] and A␤ in cerebral vessels [82] Common in A␤PP transgenic mice [231] NFTs Common, composed of paired helical filaments (PHFs) [1, 7, 14, 20, 47, 225, 275, 279] Uncommon [44] , but when present, composed of PHFs [45] Common but morphologically and topologically distinct from those in AD (due to species-specific differences), composed of straight filaments [298, 300, 301] . Nonetheless, both share the immunoreactivity for phosphorylated tau and NF proteins [302] [303] [304] Uncommon in rats but their main component, hyperphosphorylated tau, is common [305] g/g dry weight [82] Al localizationcellular and subcellular NFTs, amyloid plaques, neuronal nuclei, throughout cells, perinuclei and granulovacuolar degeneration [42, 47, 59, 174, 247, 307] Generally, uniform [59] NFTs, neuronal nuclei [59] Neuronal nucleoli, nuclei, throughout cells, granulovacuolar degeneration [70, 82, 83, 231, 305] Al localizationtissue Largely restricted to specific compartments of the brainhippocampus, cortex [41, 46, 47, 49, 247, 296] In the brain: focal accumulations are sometimes observed in the hippocampus and cortex [44, 173] . In other tissues: primarily bone and red blood cells, giving rise to bone disease-osteomalacia (or renal osteodystrophy) and microcytic anemia [56, 57, 179, 180, 308] . Parathyroid gland, joints, lung, heart, liver, spleen, muscle, skin and hair may also be affected [56, 179, 180, 252] May depend on the site of injection [301] Largely restricted to specific compartments of the brain-hippocampus, cortex, red blood cells, kidney tubules [2, 48, 70, 82, 83, 165, 231] Reversal by DFO Partially effective, slows down progression but does not reverse AD [60] . Recent experiments show that a combination of two Al chelators, ascorbate and Feralex-G, is effective in removing Al from the nuclei and hence a potentially useful pharmacotherapeutic approach to AD [278, 309] Effective [180, 310, 311] NFTs reversed by DFO in rabbit brains [302] -animals, contrasts with the insidious and latent development of neurological deficits in AD (Table 2) . Moreover, brain biopsy samples show that in spite of high overall Al brain burden, intranuclear Al is not significantly elevated in dialysis dementia patients [59] . Finally, while chelating Al by desferrioxamine (DFO), successfully reverses dialysis dementia, it is less effective in improving the clinical outcome of AD (Table 2 ) [60] . Taken together, these discrepancies have been historically used to dismiss the significance of Al toxicity in AD. Nonetheless, such dismissals may not be warranted as it is well known that the severity and clinical outcome of metal intoxication primarily depends on the dose, route, and duration of exposure as well as species differences. Al is no exception [6, [61] [62] [63] [64] . In addition, intranuclear Al is particularly resistant to removal by chelating agents [65] , and this most likely accounts for decreased responsiveness to DFO treatment in AD patients. Furthermore, a possible explanation for the absence of widespread neurofibrillary tangle-like pathology in dialysis patients which is so typical of AD, as well as animal models of Al-induced neurofibrillary degeneration (Table 2) , may be the presence of oxygenated metabolites capable of binding Al and modifying its toxic action. Such metabolites would be expected to accumulate in abnormal amounts due to chronic renal failure [15] . Noteworthy, the significance of Landsberg et al. [54, 66] work is questionable due to a number of inconsistencies for which no adequate explanation is provided. For example, Landsberg et al. produced a subsequent paper in 1993 in which they were able to detect Al in plaques of AD brains [66] , contrary to their widely cited precedent study [54] . This is despite the fact that their detection method in the former experiment was stated as being three times more sensitive. Nonetheless, they suggest that Al presence in stained plaques was due to a contamination of a staining solution [66] . In addition, Landsberg et al. provided no data in regards to the elemental content on NFTs [54, 66] where Al is known to accumulate in high amounts and concluded that Al does not have a role in AD. Resolving this dilemma, Walton et al. [67] used 26 Al isotope and ultra sensitive accelerator mass spectrometry (AMS) which enabled them to study Al toxicokinetics at physiologically relevant levels of Al exposure in rats ( 26 Al can be quantified by AMS with extreme sensitivity, ∼1 × 10 6 atoms as the 26 Al : 27 Al ratio [33, 68, 69] . Their results showed that trace amounts of Al from the equivalent of a single glass of water readily entered the brains of rats [67] , thereby providing the most compelling evidence to date against the hypothesis that the accumulation of Al in neurons is an artifact.
AD
Finally, it should be fairly obvious that AD does not result from a direct intracerebral injection of a sub-lethal dose of Al routinely used in animal models of neurofibrillary degeneration, nor sub-acute intravenous exposure commonly associated with dialysis dementia (Table 2 ). Accordingly, the prolonged clinical course of AD is suggestive of a chronic life-long exposure to low doses of a neurotoxicant such as Al [6, 48] . Consistent with this and more relevant to human exposure, recent studies by Walton [2, 48, 70] show that chronic ingestion of Al in rats, in amounts equivalent to those humans routinely ingest, results in neuropathological outcomes characteristic of AD, including cognitive deterioration, hippocampal, and cortical increases in A␤PP expression and deposition and higher Al content in the perikarya of pyramidal cells. Walton's work [2, 48, 70] demonstrates how small doses of a known neurotoxicant can accumulate over lifetime in sufficient amounts to trigger a neurodegenerative disease in otherwise healthy animals with no obvious genetic predispositions.
BIOAVAILABLE ALUMINUM
As noted by Exley et al. [37] "In the absence of recent human interference in the biogeochemical cycle of aluminium the reaction of silicic acid with aluminium has acted as a geochemical control of the biological availability of aluminium." Unlike manufactured Al compounds (such as food additives), naturally occurring compounds such as aluminosilicates (essential components of rock and soil minerals) are poorly absorbed and insoluble at neutral pH [38] [39] [40] . Al easily transits from solid to liquid phase at low pH values, and is quickly mobilized by acid rain which results in its accumulation in plants and natural water systems [38, 39, 57, 71, 72] . Surface waters have naturally a much higher Al content than ground waters [57, 73] . Notably, human exposure to Al was rather limited up until late 1880s, when Al production increased for industrial and commercial purposes [74] . Thereafter, Al salts were introduced in rapid water filtration systems for water purification purposes, to reduce organic matter, turbidity, and microorganisms [71] . Al sulfate is the most commonly used flocculant [39, 71] , thought to reduce particulate forms of Al (and this presumably decreases the total Al water content). However, flocculation by Al sulfate frequently increases the levels of the more toxic soluble monomeric inor- ganic forms in the finished water ( Fig. 3) [39, 75, 76] . Interestingly, during a survey of 186 randomly selected community water supplies in the USA, Miller et al. [73] noted that there was a 40 to 50% chance that the total Al content in the finished water (0.014-2.67 mg Al/L) would be above the original content of un-treated natural water (0.014-0.29 mg Al/L ground water and 0.016-1.17 mg Al/L surface water). Noteworthy, in certain cases Al-treated water had more than double the Al content of the naturally more contaminated surface water (2.67 vs 1.17 mg Al/L) [73] . Of significant concern is the presence of potentially extremely toxic fluoroaluminates (AlF − x ), which form in aqueous solutions containing fluoride anions and trace amounts of Al [39, 77] . These complexes act as structural analogues of PO 3− 4 in cellular signaling cascades and have the potential to cause numerous adverse systemic effects in humans [77] [78] [79] [80] [81] . Furthermore, fluoroaluminates are easily transported across the blood brain barrier (BBB), and in rats, chronic dietary exposure to AlF − x complexes causes severe damage to cerebrovascular endothelia and neurons, in a region-specific manner reminiscent of AD [82, 83] . The enhanced toxicity in the fluoroaluminate group (compared to that treated with sodium fluoride), resulted from the ingestion of an additional 0.1 mg Al/kg bw/day [82] . From these observations it is evident that in the presence of fluoride, only trace amounts of Al are needed to produce substantial neuronal injury. Both fluoride and Al when complexed in AlF -x appear to be more easily absorbed from the gastrointestinal (GI) tract compared to their ionic forms [39, 82, 83] . In spite of these observations, water fluoridation persists in USA, Canada, Australia, and New Zealand while most of Europe has abandoned this practice [77, 84] . Of note, contrary to World Health Organization (WHO) predictions, the incidence of dental caries has decreased significantly after the suspension of water fluoridation in Japan and many European countries [84] . In fluoride-treated water, fluoroaluminates are the prevalent species [39] . The enhanced transport of fluoroaluminates across the GI tract and the BBB, in context to their highly neurotoxic potential, raises significant concerns about the prevalence of these compounds in drinking water of various countries [82, 83] .
The first case of AD was reported in Frankfurt ∼20 years following the expansion in use of Al products "The case presented even in the clinic such a different picture, that it could not be categorised under known disease headings, and also anatomically it provided a result which departed from all previously known disease pathology" (Dr Alois Alzheimer) [85] . Alzheimer's astute observations were later supported by a report in Lancet, which affirmed AD as a rare condition (by 1926, a total of 33 cases of AD have been confirmed) [86] . Al is now widespread, AD affects ∼24.3 million of the world's population (a new case is diagnosed every 7 seconds) [11] , and most people are unaware of their chronic routine exposure to Al compounds (Tables 3-6) . Al is present in natural as well as processed foods, beverages, pharmaceuticals, vaccines, cosmetics, and many modern life-style utilities (Tables 3-5) [38, 39, 72, [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] .
Since 1989 a considerable number of studies have related elevated Al levels in water to an increased risk of cognitive impairment and Alzheimer-type dementia [99] [100] [101] [102] [103] [104] [105] , especially in conditions of low silica content [102, 104, 106] . Recently Campbell et al. [107] 
Provisional Tolerable Weekly Intake) is based on orally ingested Al, generally only 0.1-0.4% of Al is absorbed from the GI tract, however, Al may form complexes with citrate, fluoride, carbohydrates, phosphates and dietary acids (malic, oxalic, tartaric, succinic, aspartic and glutamic), which may increase its GI absorption (0.5-5% [38, 39] ). Co-exposure with acidic beverages (lemon juice, tomato juice, coffee) also increases Al absorption as well as conditions of Ca 2+ , Mg 2+ , Cu 2+ and Zn 2+ deficiency [38, 57, 178, 195] .
‡ A single dose of vaccine delivers the equivalent of 204-1284 mg orally ingested Al (0.51-4.56 mg), all of which is absorbed into systemic circulation [117, 118] . Al hydroxide, a common vaccine adjuvant has been linked to a host of neurodegenerative diseases, it also induces hyperphosporylation of MAP tau in vivo [87, 129, 314] .
§ The risk of antiperspirants is both from dermal exposure and inhalation of aerosols. Inhaled Al is absorbed from the nasal epithelia into olfactory nerves and distributed directly into the brain [118, 313] .
have validated concerns over Al in drinking water by demonstrating that exposure to low levels of Al lactate (0.01, 0.1, and 1 mM) in drinking water for 10 weeks increased inflammatory processes selectively in the brains of mice (as no parallel changes were observed in the serum or liver of treated animals). The authors noted that the lowest of these levels are in the range found to increase the prevalence of AD in regions where the concentrations of the metal are elevated in municipal drinking water [108] . Nonetheless, as pointed out by Rogers and Simon [91] (authors of the sole study that assessed the role of dietary Al in relation to AD), they have all ignored one of the most important sources of Al for an average citizen: food (representing ∼95% of the daily oral intake) [88] . Although average estimates of total daily intakes vary between 2 and 25 mg Al/day (14-175 mg/week) [38, 89, 94, 109] , individual intake in urban societies can easily exceed 100 mg/day (700 mg/week; Table 3 ) due to a widespread increase in consumption of processed convenience foods which are typically high in Alcontaining additives (Table 4 ). In 2006, the Food and Agriculture (FAO) WHO Expert Committee amended their provisional tolerable weekly intake (PTWI) for Al from 7 mg/kg/bw (490 mg/week, for an average 70 kg human) to 1 mg/kg/bw (70 mg/week) [110] . The Committee concluded that "aluminum compounds have the potential to affect the reproductive system and developing nervous system at doses lower than those used in establishing the previous PTWI and therefore revised the PTWI" [110] . The take home message is that a large proportion of people are unwittingly consuming significantly more Al than what is considered safe by the expert food authorities (Tables 3 and 5) .
Of particular concern is exposure to Al in children through diet and vaccination programs. Infants are at particular risk, as are all those under 5 years of age, since the BBB in young children is immature and more permeable to toxic substances [38, 110, 111] . Unfortunately, these are also the groups that obtain most Al from both of the aforementioned sources (Tables 5 and 6 ). According to the latest vaccination schedule, every child in the USA will receive a total of 5-6 mg of Al by the age of 2 years, or up to 1.475 mg of Al during a single visit to the pediatrician (Table 6 ). This is contrary to the upper limit of 5 g Al/kg/day set by the Food and Drug Administration (FDA) for premature neonates and individuals with impaired [88, 177] .
‡ SALP-acidic sodium Al phosphate.
kidney function [112] . Healthy neonates may be able to handle more Al, however, there are no such studies available upon which we could safely estimate acceptable upper levels of Al from parenteral or injectable sources in healthy children. In that respect, it is worth noting that the FDA document states that Al accumulation at levels associated with central nervous system and bone toxicity may occur at even lower rates of exposure [112] . Thus, a baby weighing ∼3 kg (6.6 pounds) at birth, receives a potentially toxic dose of Al that is 17-30 times greater than the best currently available estimate of 5 g Al/kg/day, and that from a single HepB vaccine (Table 6 ). At their 3rd regularly scheduled vaccination appointment, babies weighing ∼5.5 kg at two months (12 pounds), receive 45 to 50 times more Al than what is considered safe by the FDA (Table 6 ). The long-term consequences of such an aggressive vaccination policy have not been adequately investigated, although it is interesting to note that since the dramatic increase in the number of vaccinations deemed to be required prior to school entry (from 10 in the late 70s to 32 in 2010, 18 of which contain Al adjuvants; Table 6 ), the prevalence of neurological disorders in children in developed countries has increased by 2000-3000% (from less than 5 per 10,000 [113] to 110-157 per 10,000 [114, 115] ). What those who are pro-vaccination assert is that vaccines contain similar amounts of Al to those found in infant formulas [116] . What they fail to stress is that unlike dietary Al of which only ∼0.25% is absorbed into systemic circulation (Table 3) , Al from vaccines is absorbed at nearly 100% efficiency [117, 118] . Moreover, the sizes of most antigen-Al complexes (24-69 kDa [119, 120] ), are higher than the molecular weight cut-off of the glomerulus of the kidney (∼18 kDa [121] ), which would preclude efficient excretion of Al adjuvants. Thus, vaccine-derived Al would have a much greater potential to induce neurological damage than that obtained through diet. It is true that vaccines are not administered on a daily basis; however, they are administered frequently during the most critical period of brain development (Table 6 ) [38, 111, 122] . Further concern about neurotoxicity risks from Al vaccine adjuvants is warranted by the fact that even adults may be susceptible to adverse effects from these compounds [123] [124] [125] [126] [127] [128] . In addition, injection of Al hydroxide in amounts relevant to human vaccine exposure, leads to motor neuron death, increase in brain inflammatory markers, impairments in motor function, and decrements in spatial memory in young outbred CD-1 male mice [87, 129] . Table 6 Al administered to children under the current USA vaccination program [316] . Children from 2-18 months of age who regularly receive multiple vaccinations may exceed current FDA safety limits for Al exposure from parenteral sources (5 g Al/kg/day [112] ) by a factor of 50. Note that these FDA guidelines would be applicable to vaccination since all Al injected from a vaccine would eventually be absorbed into systemic circulation [118] . By 2 and 6 years of age, children receive a total of 5.2-5.9 mg Al and 5.8-6.5 mg Al respectively. HepB-Hepatitis B, RV-Rotavirus, DTP-Diphteria, Tetanus, Pertussis, Hib-Haemophilus influenza type b, PCV-Pneumococcal, IPV-Inactivated Poliovirus, MMRMeasles, Mumps, Rubella, Var-Varicella, HepA-Hepatitis A. Regarding other sources of Al exposure in children, according to ATSDR [38] , ∼50% of them over the age of 6 months consume more than their PTWI limit for Al, while the remaining 50% are within the upper range (Table 5) . Two-year olds consume almost three times their PTWI limit (Table 5) , while infants (0-3 months) fed exclusively with certain soy-based formulas may ingest as much as 1.5 mg Al/day, which is ∼250 times the amount they would get from mother's milk and almost three and a half times over their PTWI (Table 5) . Out of all infant formulas, highest levels of Al are found in highly processed soy formulas (up to 2.5 mg Al/L), and lowest in products that require no or minimal processing and have few additives, such as human milk (unless the mother consumes a high level of Al additives) and bottled glucose water (<0.05 mg Al/L; Table 4 ). Al additives are also widely used as preservatives, emulsifiers, leavening, anticaking, and coloring agents [38, 72, 88-91, 93, 94, 97, 98, 130] . Among the most common are: 1) basic sodium Al phosphates (SALPs), emulsifying agents in cheese, and 2) acidic SALPs (which react with sodium bicarbonate to cause a leavening action), used in commercial baking powders, biscuit, pancake, waffle, cake, doughnut, muffin, and self-rising flour mixes [88, 89, 97, 98, 130] . A single serving of a ready-to-eat pancake may yield 4 times the Al PTWI (180 mg; Table 4 ), while a typical serving of processed cheese (28 g) may provide ∼11.5-40 mg of dietary Al (1/7 ->1/2 the PTWI; Table 4 ). It is worth noting that the same processed food items (including soy infant formulas), which contain Al, often also contain potentially excitotoxic amounts of monosodium glutamate (MSG) [131, 132] . Glutamate significantly enhances Al transport across the BBB and accumulation in AD-susceptible regions (Fig. 4) [133] [134] [135] . It may also increase Al absorption from the GI tract [39, 136] ). Conversely, Al potentiates glutamate excitotoxic effects in vivo [135] in cultured hippocampal pyramidal neurons [50] and in primary neuronal cultures (Table 1 ) [137] . Notably, neuronal lesions resulting from synchronistic application of Al and glutamate show mitochondrial abnormalities which are characteristic for early excitotoxic events (swelling and disruption of the mitochondria and microvacuolization of the perikaryal cytoplasm) [50] .
As early as 1911, William Gies expressed concerns about the use of Al in baking powders [98] . Based on seven years of research on the effects of Al salts in animals and humans, Gies concluded that Al should be excluded from food in the interest of conservation of the most valuable natural resource: human health [98] . More recently, Rogers and Simon [91] who conducted the sole preliminary study to determine whether dietary Al intake differs in individuals with and without AD (and found that AD subjects consumed significantly more of the highest SALPcontaining food category, p = 0.025), noted: "Current dietary patterns in the USA are akin to a grand-scale experiment whereby some individuals are consuming large quantities of aluminum while others are not, the long term effects of which have not been investigated. It is important to determine whether William Gies was correct in his admonitions". Interestingly, the 357 page ATSDR report [38] states that "Oral exposure to alu- Fig. 4 . Major routes of Al transport in and out of the brain: from the blood, Al enters the brain ECF primarily through the BBB via transferrinmediated uptake. Al influx from the brain ECF to the cellular compartments is mediated by transferrin-dependent and independent mechanisms. Neurons and glia compete for Al uptake from the brain ECF, however, long-lived terminally differentiated neurons tend to accumulate more Al over time. Some Al in the brain is rapidly effluxed as Al-citrate by the MCT-transporter. A significant portion of Al is retained in the cellular compartments (nucleus, ER, bound to ATP or membrane phospholipids). BBB-blood brain barrier, CP-choroid plexus, CSF-cerebrospinal fluid, ECF-extracellular fluid, MCT-monocarboxylate transporter, Glut-glutamate transporter. The dashed line represents the absence of a membrane barrier between the CSF and brain ECF (adapted from Yokel et al. [68] ). minum is usually not harmful", although it recognizes that the neurological effects of such exposure have not been "adequately investigated in healthy humans". The report further notes that "There is a rather extensive database on the oral toxicity of aluminum in animals. These studies clearly identify the nervous system as the most sensitive target of aluminum toxicity" [38] .
The data presented by the ATSDR in relation to Al toxicity following dermal and inhalation exposures in humans is equally scant. [38] . The ATSDR then makes a claim that "Aluminum compounds are widely used in antiperspirants without harmful effects to the skin or other organs" [38] . The study which the ATSDR uses to back their conclusion on the safety of antiperspirant use dates back to 1974 [138] , even though there are several more recent reports which implicate antiperspirant use with the increased risk of Al-related diseases, including AD [92, [139] [140] [141] . Similarly, in response to concerns raised by citizens in regards to the safety of Al-based antiperspirants, the FDA asserts that it "has no data showing that products containing up to 35 [143] .
In contrast to such statements, there is solid evidence implicating even less common routes of Al exposure, such as inhalation, in preclinical cognitive and behavioral disorders which might prelude AD [144, 145] .
MECHANISMS OF ALUMINUM TOXICITY

Physical and chemical properties: aluminum's toxic mimicry
Much like mercury, and unlike iron, copper, zinc, and manganese, Al has no biological role and is unquestionably a neurotoxin [32, 38, 39, 146] . A small ionic radius and high charge are main properties by which Al exerts its neurotoxic activity. The Al ion (0.054 nm) is roughly the same size as the ferric ion (0.065 nm) and much smaller than magnesium (0.072 nm) and calcium ions (0.100 nm). In biological systems, Al can effectively replace these essential biometals in many enzymatic reactions [39, [147] [148] [149] [150] [151] . For example, Al binds the extracellulariron carrier transferrin [19, 146, 152] which in turn, may facilitate its transport across the brain barriers (Fig. 4) . Furthermore, due to its greater affinity for anionic groups, Al potently interferes with reactions that depend on reversible dissociation. Processes involving rapid Ca 2+ exchange are inhibited by Al substitution [6, 39, 150, 151] . Similarly, at nanomolar concentrations, Al inhibits many Mg 2+ and ATP-dependent enzymes, including: tubulin GTPase [149] , Na + K + ATPase [153] , hexokinase [146, 154] , RNA polymerase [155] [156] [157] , choline acetyltransferase [158] [159] [160] , ferroxidase (ceruloplasmin [161] ), calmodulin-dependent ATPase [6, 148, 150] , as it binds ATP in a complex that is several orders of magnitude more stable than that with magnesium (the association constant for Al 3+ is 10 7 times that of Mg 2+ [149] ).
Al also binds other nucleotides (GTP and CTP) [162] as well as phosphate headgroups of lipid moieties in membrane systems. Apart from altering membrane properties [163] , it has the potential to interfere with any reaction that requires phosphoryl transfer and ATP/GTP hydrolysis [6, 39, 147] . As mentioned previously, Al in solution readily associates with fluoride to form highly toxic fluoroaluminate complexes, which are well known to interfere with the activity of G-proteins and calcium homeostasis [39, [77] [78] [79] [80] [81] . Given the ubiquity of enzymatic systems and signaling cascades that depend on GPCR signaling, phosphorylation, ATP, GTP, calcium, magnesium, and iron, the spectrum of physiological processes that can be adversely affected by Al is extremely vast. In spite of this, in the absence of chronic renal failure, the toxic effects of Al (especially at low doses) appear to be primarily manifested in the brain (Table 1) 
Regulation of body aluminum burden: neurotoxicity increases with aging
In the human body Al burden is partitioned at four levels: GI tract, blood-kidneys, brain barriers, and brain extracellular fluid (ECF) [6, 27, 39, 68, 175, 176] . While the efficiency of absorption from the GI tract and removal by the kidneys determines the amount of Al in the blood, regulation at the brain barrier/brain ECF levels determines where in the brain Al is distributed [6] . Systemic regulation of Al is far more complex than initially thought as there are numerous factors that affect Al partitioning at all four levels (Table 3 -see footnote; Fig. 4) [6, 38, 39, 88, 93, 109, 135, 136, 177, 178] . The regulation of the Al burden by the brain is geared towards maintaining optimal neuronal function [6] . There are specific transport mechanisms which ensure active and dynamic distribution of the Al burden in the brain and this partially mitigates its neurotoxic effects [6, 63, 68, 175] . These observations indicate that the earlier animal models of neurofibrillary degeneration (based on intracerebral injection of Al), may not be adequate in assessing the significance of bioavailable Al in the etiology of AD. Likewise, dialysis dementia is not representative of a truly chronic exposure to dietary ingested Althe chief risk for the majority of people, as the GI barrier is bypassed by intravenous dialysate delivery. Furthermore, patients with disabled urinary clearance undergoing chronic treatment with Al-contaminated dialysate, accumulate Al in tissues other than brain (primarily bone and red blood cells; Table 2 ) [56, 179, 180] . In contrast, in healthy people only a minor fraction of Al is absorbed from the GI tract (<1%) [33, 39, 88, 93] , which is then in large proportion removed by the kidneys. Hence, symptoms of Al intoxication only become apparent when kidney function is impaired, which occurs normally during aging as humans lose up to 50% of their glomeruli between 40 and 85 years of age [181] . Kidneys are a major route by which metals are excreted from the blood, and their essential role in eliminating excess Al is emphasized by in vivo observations which show that concurrent with neurodegeneration, Al intoxication is often accompanied by elevated Al kidney burden, glomerular distortions, and renal failure [82] .
Thus, when urinary clearance is impaired, the risk of Al neurotoxicity significantly increases as it increases the Al brain burden. This implies that a strong predisposition for gradual accumulation of metabolic errors consequent to Al toxicity, is somewhat inherent to the aging process and explains how a life-long exposure to low doses of Al could lead to Al accumulation in neural cells and instigate a progressive cascade of subtle neuropathological events that culminate in AD. This contention is supported by the late age of onset of clinical symptoms (>65 years) and relatively slow progression of idiopathic AD (average duration of illness is 10 years; Table 2 ), as well as experimental evidence: 1) older persons have typically higher brain Al content than younger ones [41] , and subjects with AD have an even higher content than non-demented age-matched controls (Table 2) , 2) lower levels of serum Al than those routinely reported in dialysis patients are known to produce cognitive impairments associated with AD [169] . Performance in behavioral tests correlates with serum Al levels in elderly subjects and elevated Al is associated with impaired visuo-motor coordination, poor long-term memory and increased sensitivity to flicker. Remarkably, the same effects are seen in rats chronically fed with Al [169] . 3) Analysis of brain tissue from AD patients shows a stage-specific accumulation of Al in hippocampal neurons [47] , 4) the studies of Walton [2, 48, 70] , elegantly demonstrate that in rats, even at low doses, chronically administered dietary Al preferentially accumulates in AD-susceptible brain compartments, at levels sufficient to up-regulate A␤PP mRNA and protein expression.
The implication of these observations is that incremental acquisition of small amounts of Al (as through dietary intake), favors its selective accumulation in brain tissues. The association between distribution of brain Al and AD pathology likely implicates specific transport mechanisms, both circulatory and at the level of brain barriers/brain ECF. Less likely, however, remains the possibility that such compartmentalized distribution reflects the impact of transport by non-Al specific processes.
Aluminum toxicokinetics across the brain barriers: more than just diffusion
Normal brain function is critically reliant on the efficacy of brain barriers to maintain the delicate neurochemical balance between neurons and their synaptic connections [111] . Both, the BBB and the choroid plexus (CP), play major roles in maintaining this balance by regulating the exchange of substances between the blood ECF (plasma) and brain ECF (Fig. 4) , and thus any agent that can alter membrane properties has a potential to initiate neurotoxic events. Alteration in brain barrier permeability is not a prerequisite for Al entry into the brain, as Al sequesters a myriad different transport mechanisms to actively traverse membrane systems, including receptor mediated endocytosis and carrier-mediated transports (Fig. 4) . The surface area of the BBB capillaries in humans is ∼12 m 2 , which is ∼10,000-fold that of the choroid plexus (10 cm 2 ) and experimental evidence strongly implies that plasma Al gains entrance to the brain ECF via the BBB route, rather than through the CP (Fig. 4) [68] . Furthermore, the kinetics of brain Al transport unequivocally points to a carrier-mediated process and not passive diffusion [27, 63, 68, 175] . Once in the brain ECF, Al will either bind to polar headgroups of membrane phospholipids, or enter intracellular pools, most probably via transferrin uptake, monocarboxylate transporter (MCT) -and/or organic anion transporter-mediated mechanisms [6, 27, 68, 152, 175] . Endoplasmic reticulum (ER), nuclear chromatin, hyperphosphorylated tau, and ATP are believed to be the major binding targets of intracellular Al [6, 174, [182] [183] [184] . Repeated chelation therapy with DFO in 26 Al-treated rats shows that some Al persists in the brain for a long time (half-life of brain 26 Al was estimated to be 150 and 55 days in the control and DFO-treated group respectively) [68] . These data indicate that Al is tightly bound to intracellular pools and are consistent with frequent observations of perinuclear and nuclear foci of Al in AD brains [10, 42, 47, 59, 182, 185] .
Pyramidal neurons are a population of brain cells that are particularly susceptible to Al accumulation and toxicity [2, 43, 47, 50, 70] . These are also the largest cells in the brain and one of the most vulnerable cell populations in AD [1, 10, 43, 186, 187] . Cognitive abilities as well as psychomotor control are intimately associated with function of pyramidal cells [188, 189] . It is well known that brain tissue has a limited proliferative capacity and as such, an intrinsic tendency for accumulating metals [19, 146, 152, 190] . Toxins are diluted in undifferentiated cells undergoing mitosis. However, because pyramidal neurons are terminally differentiated, the Al transported into these cells will tend to accumulate over time. When accumulation of metabolic errors at susceptible foci exceeds a certain threshold, as a result of persistent latent Al toxicity, clinical symptoms will become apparent. Consistent with this hypothesis, abnormally high levels of Al are routinely found in AD brains, up to fourfold the level of healthy controls (Table 2 ) and sensitive quantifying techniques demonstrate that perikarya of pyramidal cells of the hippocampus and entorhinal cortex are foci where Al accumulation is most pronounced, while interneurons are spared [2, 43, 47, 50] .
It is quite clear that Al partitioning within the brain is highly complex and dynamic (Fig. 4) . There are three principal sources of bioavailable brain Al: extracellular, membrane-bound, and intracellular. There is also a further sub-partitioning among these sources. Unlike the former two, the intracellular Al pool does not appear to be readily mobilized as the kinetic control at the level of terminally differentiated neurons favors its accumulation (Fig. 4) . This provides the basis for a region-specific accumulation of Al, in a manner that highly implicates its involvement in AD.
Fate of dietary aluminum: implications for dysregulation of iron homeostasis and oxidative damage
Al absorbed from the GI tract either becomes rapidly bound to various high-molecular-weight carrier proteins (including the iron-specific carriers transferrin and ferritin as well as ␣ 2 -macroglobulin, immunoglobulin, hepatoglobin, and albumin) [19, 27, 68, [191] [192] [193] or by low-molecular ligands such as citrate (Fig. 4) [27, 175] . Experimental evidence has suggested that at equilibrium, 80-90% of total Al in the plasma is carried by transferrin [39, 68, 192] , the chief iron transport protein in vertebrates [19, 25, 152] . Although the relative proportions of different Al complexes may be different in non-equilibrium [194] , it is the high molecular weight-bound fraction of plasma Al (such as transferrin-Al) that is perhaps more biologically relevant, since it is refractory to excretion by the kidneys [38, 93] . Transferrin has a similarly high affinity for Al 3+ ions as for Fe 3+ ions [152] and typically, even under conditions of iron overload, only 30% of transferrin is occupied by iron [19] . This leaves a potentially high fraction of free transferrin avail-able to Al and other metal ions which have been shown to bind transferrin (zinc, gallium, manganese) [152] . The cellular intake of transferrin-bound iron occurs via transferin receptor (TfR)-mediated endocytosis of the TfR-transferrin (iron) complexes [27, 68, 152, [195] [196] [197] . Several reports indicate that density and binding to TfRs is decreased in AD. Morris et al. [196] report a reduction in binding to TfRs in pyramidal cell layers of the hippocampus in AD brains, which led them to conclude that TfR-mediated Al uptake is not a major contributor to AD. However, such localized loss of TfR-mediated endocytosis would not significantly affect hippocampal Al uptake since it is estimated that only ∼4% of Al within the brain ECF pool is bound to transferrin and ∼90% is bound to citrate, a vehicle for the MCT transporter (Fig. 4 ) [68] . Furthermore, Al is known to use TfR-independent mechanisms to gain access to brain compartments from the brain ECF and the most likely candidate for this process is citrate, the major Al carrier in the brain ECF (Fig. 4) [27, 68, 175] . Most notably, recent research evidence shows that Al-transferrin complexes are not bound by the TfR [198] [199] [200] because of an incomplete open/closed form which precludes them from forming specific ionic inter-residual interactions, such as those formed by iron-transferrin and the TfR [198] . This implies that Al-transferrin transfer from the blood stream to cytoplasm may not follow the classical iron-TfR acquisition pathway. Nonetheless, cellular uptake of Al-transferrin complexes has been observed in different cell lines [201] [202] [203] [204] indicating that such complexes may be utilizing a yet unknown mechanism by which they circumvent the incompatibility with the TfR to gain access to the intracellular milieu. Apart from transferrin, Al may also bind to the chief iron storage protein ferritin, and according to a study by Fleming and Joshi [205] , ferritin-bound Al isolated from AD brains is 6-fold higher than that from age-matched controls. Nonetheless, some investigators have reported relatively little Al in ferritin deposits [206, 207] , suggesting that less Al is sequestered and more is freely available to cause damage in cells [206] .
Free iron is thought to be a principal mediator of oxidation in cellular systems due to its ability to generate highly reactive oxidative species (ROS) via Fenton chemistry [19, 26, 137, [208] [209] [210] . Unlike iron, Al is redox inert and its ability to induce oxidative damage is related to a synergistic action that involves iron [209, 211, 212] . Experimental evidence suggests that senile amyloid plaques can act as sinks for free metals, both redox active (iron and copper) and redox inactive (zinc and Al) [213] . In addition, it has been shown that A␤ 42 can influence the Fenton chemistry through aggregation state-specific binding of both ferrous iron, Fe(II) and ferric iron, Fe(III). According to Khan et al. [213] , the net result of these interactions was a delayed precipitation of redox-inactive iron (III) hydroxide, Fe(OH) 3 , such that Fe(II)/Fe(III) were cycled in redox-active forms over a substantially longer time period than if peptide had been absent from preparations. Further aggregation state-specific binding of both Fe(II) and Fe(III) determined critical equilibria involved in the formation of hydrogen peroxide via the superoxide radical anion in favor of maintaining Fe(II) in solution [213] . The additional presence of Al, copper and zinc influenced both the aggregation state of A␤ 42 , and therefore its binding of Fe(II) and Fe(III), as well as the redox chemistry, most specifically through direct interactions with the superoxide radical anion which is heavily implicated in ROS mediated neurotoxicity [213] . Finally, it was demonstrated that the addition of pathophysiologically significant concentration of Al exacerbated superoxide radical anion -induced toxicity in the presence of A␤ 42 while both copper and zinc, mitigated against oxidative damage but only providing that Al was absent [213] .
In conclusion, it is evident that by hijacking several cellular transport mechanisms, Al gains direct access to brain tissue, and that not all areas of the brain are equally capable of removing the burgeoning Al burden. Thus, long-term, the overt manifestations of Al neurotoxicity may not be determined by the rate of Al influx as much as Al efflux. Taken together, these observations nullify the arguments that Al cannot enter the brain actively and/or in sufficient amounts to cause damage, and that cellular transport routes are not effectively exploited by Al to the extent in which it could have an impact on AD. Because of its high neurotoxic potential, the factor that is of particular relevance in regards to the risk for AD, is that small amounts of Al can access the brain continually, to a point at which neurotoxicity occurs. As documented (Tables 3-5) , this criterion is satisfied through dietary Al intake.
BRAIN COMPARTMENTALIZATION: BASIS FOR ALUMINUM'S SELECTIVE NEUROTOXICITY IN AD
Interference with glucose metabolism and damaging effects on the myelin sheath
What makes the brain in general and certain brain areas specifically more susceptible to Al toxicity? In answering these questions, it should be emphasized that brain is a highly compartmentalized organ, both at systemic, tissue, as well as cellular levels. On a systemic level, the brain has intrinsically high glucose and oxygen requirements [19, 214, 215] , high surface area of biological membranes (especially vascular endothelium) [68] , high tubulin content [20] , high phospholipid content, and a low concentration of antioxidants, compared with other organs [212, 215, 216] . For example, although an adult human brain only weighs ∼1.5 kg, it consumes 20% of total body oxygen and 120 g of glucose/day, compared to 190 g for the whole body [19] . Furthermore, the utilization of glucose varies in response to different stimuli and among brain compartments [217] . More than 80% of brain glucose is used in the glycolytic pathway that requires ATP/magnesiumdependent activity of hexokinase, while the rest is metabolized by the glucose-6-phosphate dehydrogenase (G6PD)-dependent shunt pathway [19] .
Experimental evidence has shown that Al interferes with glucose metabolism by inhibiting both hexokinase and G6PD [19, 146, 154] . The latter is of special significance since the shunt pathway is primarily utilized by myelinated neurons and its activity is dependent on the degree of myelination [218] . Furthermore, as shown by Verstraeten et al. [212] , Al (due to its lipophilic nature), binds avidly to membrane phospholipids and by inducing changes in phospholipid rheology (Table 1) , promotes lipid peroxidation (LPO). Consequently, myelin (due to its high lipid to protein ratio, 70 : 30 and relatively low ubiquinol content, as opposed to synaptic membranes, 30 : 70), is the preferred target of Al-mediated oxidative damage both in vitro and in vivo [212] . Moreover, chronic oral exposure to Al in rats markedly reduces the content of specific classes of membrane phospholipids in the brain myelin sheath [216] . Specifically, Al-fed rats show a 70% decrease in acidic phosphatidylinositol (PI), phosphatidylserine (PS), and phosphatidic acid (PA), an effect which is expected to alter charge distribution and insulation properties of the myelin membrane [216] . Alterations of the myelin sheath may lead to dysfunctions in memory and cognition while a marked reduction of the brain PI content is likely to cause deficiencies in inositol phosphate (IP) signaling (Fig. 2) . Both of these effects have been observed in Al-treated animals [63, 150, 167, 219, 220] and are also common to AD [3-5, 8, 22, 23] .
It is interesting to note that the highest myelin content is associated with pyramidal cells. Studies suggest that axon collaterals of pyramidal neurons contribute most to the total myelin brain content, and that nonpyramidal neurons and afferent fibers play a minor role [221] . Moreover, it has been demonstrated that a progressive loss of myelin in the human nervous system occurs after the age of 30 years and that people suffering from presenile and senile dementia have a reduced myelin content compared to healthy people [222] . It is noteworthy that, with advancing age, there is a concomitant loss of myelin content along with the deterioration of kidney function [181] . This observation reinforces the notion that a predisposing susceptibility to Al neurotoxicity is inherently and incrementally acquired during aging, thus exacerbating the risk for idiopathic AD.
As shown by Walton, cognitively impaired Alfed rats develop substantial hippocampal and cortical lesions (related to NFTs), consisting of Al-loaded pyramidal neurons [2, 48, 70] . These cells also show significant morphological abnormalities, displaying swollen neurites with varicosities along their length, and myelin matter which is strongly immunoreactive for A␤PP [2, 70] . Finally, the progressive structural changes reported to occur during aging in cortical pyramidal neurons remarkably resemble those induced by chronic dietary Al intake and include a reduction in neurite number, length, and branching and ultimately, the appearance of varicose deformities [222] . It is tempting to speculate that these age-related neuronal aberrations may be partly due to cumulative age-dependent effects of Al toxicity.
Compartmentalization by the cytoskeleton: how aluminum triggers NFTs
The neuron is a highly cross-linked compartment with extensive transport and communication networks which are imparted by the cytoskeleton. MTs, neurofilaments (NFs), and MAPs, are essential cytoskeletal components that sustain neuronal function [20, 223] . Since breached integrity of the cytoskeleton is detrimental to neuronal function, any significant interference with its structural components can result in neuronal de-differentiation or possibly death. The brain's cytoskeletal system is somewhat unique as it achieves compartmentalization at tissue, cellular and subcellular levels. The brain has a far higher tubulin content than other tissues [20] , which may be related to its intrinsically high metabolic activity and greater distance requirements for cellular transport. There are several tubulin isoforms and their distribution varies between different brain and cellular compartments [20] . NFs localize to axons and dendrites and primarily function in stabilizing the axonal cytoskeleton and promoting neurite outgrowth [223, 224] . Adding to the complexity of the cytoskeletal lattice are the MAPs, which promote the assembly of tubulin into MT polymers [20, 223] . Furthermore, like tubulins and NFs, MAPs also tend to be compartmentalized within neurons [20] . Notably, both tau and NFs contain multiple phosphorylation sites and are subjected to regulation by various kinases and phosphatases [1, [225] [226] [227] . It is proposed that the functional compartmentalization that characterizes brain cells is enabled by a distinctive localization of cytoskeletal components.
There are numerous components of the MT system which are susceptible to Al (Table 1 ). One major mechanism by which Al preferentially impairs pyramidal neurons is by disabling their capacity for MT assembly [2, 10, 70] . This would cause disruption of axoplasmic and dendritic transports, neurite damage, and eventually, cell death [186] . Consistent with this, Al accumulation in pyramidal cells from AD brains is associated with depletion of MTs and abundance of NFTs that contain Al [2] . Accordingly, rats chronically exposed to low dietary Al show cognitive impairment concomitant with pyramidal cell Al accumulation and microtubule depletion, shriveling neurites and synapse loss [2, 70] . Likewise, Al-induced neurofibrillary degeneration in rabbits selectively affects cortical pyramidal neurons while sparing interneurons [43] .
Oxidative stress and lipid peroxidation
Oxidative damage is thought to be an early event in AD [17, 21, 228, 229] and Al is a known pro-oxidant in vivo (Table 1) [164, 166, [230] [231] [232] . Al potentiates oxidative damage by multiple mechanisms: it inhibits the key free-radical scavenging enzymes superoxide dismutase (SOD) and catalase [164] , increases LPO [212, 231] , and modulates the induction of neuronal nitric oxide synthase [232] . High metabolic activity and low free radical buffering capacity, coupled with 400 miles of brain capillaries (and associated membrane phospholipids) within the BBB [68] , make the human brain a prime target for Al-induced oxidative damage. Accordingly, oxidative stress in the brain is primarily manifested as LPO, due to its exceptionally high content of polyunsaturated fatty acids (PUFAs, constituents of membrane phospholipids), that are particularly vulnerable to oxidation [21, 229] . Isoprostanes (iPs) are chemically stable isomers of prostaglandins (formed by peroxidation of PUFAs) and specific and sensitive markers of in vivo LPO [233] [234] [235] . Studies show that levels of a major iP marker 8,12-iso-iPF 2␣ -VI are increased postmortem in AD-susceptible brain compartments [235] as well as in the urine, plasma, and cerebrospinal fluid (CSF) of patients with a clinical diagnosis of AD [234] where 8,12-iso-iPF 2␣ -VI levels correlated with disease severity. Remarkably, these observations were experimentally reproduced in a mouse model of ADlike amyloidosis (Tg2576), in which mice overexpress a double mutant human A␤PP transgene. In Tg2576 mice, chronically administered dietary Al increased 8,12-iso-iPF 2␣ -VI levels in the hippocampus and neocortex and concomitantly, also increased A␤ levels and stimulated plaque deposition [231] . Notably, none of these pathogenic changes were observed in Tg2675 mice fed a regular chow diet. Moreover, Al-induced increases in 8,12-iso-iPF 2␣ -VI levels and amyloid plaque burden in the hippocampus and neocortex were directly correlated and almost completely reversed by supplementation with antioxidant vitamin E. Furthermore, early in the course of treatment, plasma and urine 8,12-iso-iPF 2␣ -VI levels also increased in Al-fed mice, but they were reduced in mice supplemented with vitamin E [231] . These results provide compelling in vivo evidence that dietary Al can drive and accelerate the amyloid cascade by potentiating LPO and oxidative stress. They are also in concordance with emerging data from prior experiments in Tg2576 [21] , as well as studies of AD patients, which indicate that increased levels of 8,12-iso-iPF 2␣ -VI in blood or urine appear to precede the onset of AD, and that LPO is central to AD [234] . Similar effects of Al on oxidative stress were observed in rats (both adult and pups), where chronically administered Al (by daily oral gavage) significantly increased LPO and decreased the activity of two key antioxidant enzymes, SOD and catalase in specific brain regions [164] .
Effects on chromatin structure and transcription
The nucleus is another prime target for Al toxicity due to its high anionic microenvironment (Table 1 ) [155, 236] . Consistently, focal accumulation of Al in neuronal nuclei has been widely documented and recognized as a distinguishing feature in AD [42, 47, 59, 156, 174, 185] . Al binds to phosphonucleotides and alters DNA interaction with nucleoproteins, transcription factors and RNA polymerase. The effects of nuclear Al have been extensively studied and are accordingly best summarized by Lukiw et al. "The presence of aluminum is an impediment to normal brain gene function" [155] . At nanomolar concentrations, Al inhibits brain-specific gene transcription from selected AT-rich promoters of human neocortical genes [155] . Al repressive action on gene transcription is linked to its ability to: 1) decrease the access of transcriptional machinery to initiation sites on DNA template by enhancing chromatin condensation [174, [182] [183] [184] [185] , 2) interfere with ATP-hydrolysis-powered separation of DNA strands either indirectly (by binding to phosphonucleotides and increasing the stability and melting temperature of DNA) [155, 236] or directly (by inhibiting the ATPase-dependent action of RNA polymerase) [155] . These effects were experimentally demonstrated at physiologically-relevant Al concentrations (10-100 nm [155, 157] ) and at levels that have been reported in AD chromatin fractions [185] . Of particular relevance, highly condensed cortical chromatin fractions and increased linker histone content on dinucleosomes are typical features of both idiopathic and familial AD [185] . Al is well known to promote chromatin compaction by increasing the association of DNA with linker histones H1 0 and H1 [174, 182, 184, 185] . Accordingly, compared to aged matched controls, AD subjects show a nine-fold increase in Al content in the dinucleosome fraction containing repressed neuronal genes. Moreover, a highly significant correlation was found between the Al DNA ratio and the degree of chromatin compaction [65, 185] .
It is particularly interesting to note that in spite of its overall repressive action, Al can also promote transcription. Based on experimental evidence, it has been suggested that by promoting LPO and oxidative stress, Al activates the ROS-sensitive transcription factors, hypoxia inducible factor-1 (HIF-1) and nuclear factor (NF)-B and augments specific neuroinflammatory and pro-apoptotic signaling cascades by driving the expression from a subset of HIF-1 and NF-Binducible promoters [209, 237] . Out of eight induced genes up-regulated in cultured human neurons by 100 nm Al sulfate (the same compound that is used as a flocculant in water [38, 39] ), seven showed expression patterns similar to those observed in AD, including HIF-1/NF-B-responsive A␤PP, interleukin-1␤ (IL-1␤) precursor, NF-B subunits, cytosolic phospholipase A 2 (cPLA 2 ), cyclooxygenase (COX)-2, and DAXX, a regulatory protein known to induce apoptosis and repress transcription [237] . Both HIF-1 and NF-B are up-regulated in AD where they fuel the proinflammatory cycle which leads to further exacerbation of oxidative stress and inflammation, culminating in neuronal death [16, 155, 209] . The ability to induce HIF-1/NF-B-dependent up-regulation of A␤PP may well be the underpinning mechanism by which Al triggers oxidative stress-mediated amyloidosis in Tg2576 mice [231] .
Interference with neurotransmission, G-proteins, and calcium homeostasis
Dysregulation of G-protein mediated signal transduction and calcium homeostasis is central to the etiology of AD and it is thought to precede the amyloid cascade and NFT changes [4, 5, 8, 12, 238] . G-proteins and calcium modulate vital neuronal processes such as neurotransmission, synaptic plasticity, and apoptosis [3, 12, 23, 28] . Al interferes with several components of the two principal G-protein signaling pathways: GPCR-regulated 1) phospholipase C (PLC)/inositol 1,4,5-trisphosphate (IP 3 ) and 2) adenylate cyclase (AC)/cyclic AMP (cAMP) pathway (Table 1, Fig. 2 ). Alterations in both of these pathways have been demonstrated in AD brains at numerous levels [3-5, 8, 28, 239] . Explicitly, impaired response to G q -cholinergic muscarinic receptor agonist-induced PI hydrolysis by PLC, decreased levels and activity of PKC and the loss of IP 3 receptors in the entorhinal cortex and hippocampus correlate with AD-NFT pathology [3-5, 8, 239] . Disruptions in the AC pathway in AD include impairments at the level of G s -protein stimulation of AC [5] , increased cAMP in cerebral microvessels [239] and loss of calcium/calmodulin (CaM) sensitive AC isoforms [5] . Overall, G-protein levels are largely preserved in AD, indicating a functional deficit [4, 5, 8] .
Al action on G-proteins has been shown to be highly specific. While Al inhibits G q -mediated PI hydrolysis by PLC, it stimulates G s -mediated cAMP production by AC (Table 1, Fig. 2 ). Most notably, these effects were observed in vivo after chronic oral exposure to Al-treated drinking water in weanling and adult rats [167] . In summary, impaired response to agonists at G q /G s levels, elevated cAMP, PLC inhibition and IP 3 decrease and impairment of calcium/CaM-dependent enzymes are specific signatures of Al neurotoxicity (Table 1, Fig. 2 ). These changes perfectly reproduce the hallmark changes observed in AD [3-5, 8, 28, 239] . Similarly, the neurotoxic effects of Al mimic cholinergic dysfunction, another hallmark of AD, in a manner that highly implicates its central role in the pathogenesis of this disease (Table 1) . Acetylcholine (ACh) release from cholinergic neurons alters the excitability of hippocampal pyramidal neurons [150] . By interfering with G-proteins and altering calcium homeostasis, Al toxicity causes reductions in neuronal excitability, impairs neurotransmission and progressively leads to memory and learning deficits. Furthermore, by inhibiting agonist-mediated stimulation of cholinergic muscarinic receptors and disabling the IP 3 /PLC signal transduction pathway, Al may shift A␤PP processing towards an increase in production of the neurotoxic A␤-peptide, at the expense of the neuroprotective ␣-secretase-derived soluble A␤PP (s␣ -A␤PP; Table 1 , Figs 1 and 2 ). This would explain gross abnormalities in neurite morphology, losses of synapses and neurons that are seen to occur concomitantly with A␤PP upregulation in Al-fed rats [2, 70, 82, 83] . This is also consistent with the type of damage observed in AD brains [2, 70, 82, 83] , given that s␣-A␤PP function is required for proper neurite outgrowth and branching [240, 241] and to counteract pro-apoptotic signaling and synaptogenesis [241, 242] . It is worth emphasizing that Al may induce amyloidosis by up-regulating A␤PP expression, altering A␤PP processing and trafficking to increase the production of toxic A␤ species, and promoting their aggregation into fibrillar structural constituents of senile plaques (Table 1, Figs 1 and 2) . Thus, it appears that all pathological parameters required for amyloidogenesis are efficiently targeted by Al.
In summary, it is evident that the brain's structural and functional heterogeneity provides a basis for differential susceptibility of specific neuronal populations to Al toxicity. The above observations re-emphasize the hypothesis that Al aggravates the risk of developing age-related dementia of the Alzheimer type, by driving subtle though persistent incremental deterioration of neural functions at a susceptible foci.
CONCLUSIONS
Al is the third most abundant element on earth, widely bioavailable to humans and a definite neurotoxin and AD is the most prevalent neurodegenerative disease at the present age. The hypothesis that Al significantly contributes to AD, more so than any other single factor investigated, is built upon very solid experimental evidence. Al has a direct and active access to the brain where it accumulates in a region-specific manner that highly implicates its involvement in AD. Experimental data clearly shows that all neurophysiological parameters required for AD are efficiently targeted for impairment by Al. The sum of latent neurophysiological alterations which are known to precede overt clinical manifestations of AD and are consistent with Al's neurotoxic properties are: 1) enhanced amyloidosis, 2) neurofibrillary abnormalities, disruption of axonal transport mechanisms, neurite degeneration, and loss of synapses, 3) deficits in neurotransmission (particularly cholinergic) and impairment of G-protein signal transduction cascades, 4) disruption of neuronal energy metabolism and brain metal homeostasis (particularly calcium iron and magnesium), 5) potentiation of oxidative stress and peroxidation of brain membrane lipids, 6) disruption of brain barriers, 7) alterations in chromatin structure and impairment of transcription, and 8) upregulation of stress-related pro-inflammatory and pro-apoptotic pathways. The latter may be of special significance since elevated levels of intrinsic inflammation are associated with neural aging and further exacerbated in several neurodegenerative diseases. In stark contradiction with the abundance of research evidence (Table 1) , there appear to be "several hostile intellectual attitudes" [14] that reject the possibility that Al toxicity contributes to the growing incidence of AD [243, 244] . Such widely circulated opinions hamper implementation of preventative plans to lessen exposure to Al, which, according to some leading scientists' advice, would be the most sound and cost-effective approach to reduce the growing incidence of Alzheimer's type dementia [32, 33, 91, 98, 100, 245, 246] . Given the great socio-economical impact of AD, immediate steps should be taken to minimize human exposure to Al, the single most avoidable factor that poses a serious risk for developing AD. The failure of government health policy makers to take into account the most recent animal studies [2, 48, 61, 70, 82, 83, 107, 165, 167, 178, 231] , as well as epidemiological data [99] [100] [101] [102] [103] [104] [105] 108] which clearly relate long-term Al ingestion at levels relevant to human exposure to an increased risk of cognitive impairment and dementia of the Alzheimer-type, leads to human AD cases as a major means for demonstrating the neurotoxic potential of Al. This practice is unacceptable but unfortunately prevalent at the present time: "Current dietary patterns in the USA are akin to a grand-scale experiment whereby some individuals are consuming large quantities of aluminum while others are not, the long term effects of which have not been investigated" [91] . It would appear that the practical considerations of warnings given by William Gies are now 100 years overdue "These studies have convinced [98] . The same rationale would apply for Al in skin-care products, antiperspirants, pharmaceuticals, and perhaps significantly in vaccines, at least until independent research is available to demonstrate that these products can be used safely. In particular, Al in adjuvant form carries a risk for long-term brain inflammation, cytotoxicity, and associated neurological complications, and may thus have profound and widespread adverse health consequences. We are long overdue for a comprehensive evaluation of the overall impact of Al on human health. With regards to AD, such an evaluation should include studies designed to elucidate the molecular mechanisms involved in the neurotoxicity caused by chronic Al intake and its association with the metabolism of other compounds such as iron. Special emphasis should be given to Al species which are most relevant to human exposure (e.g., fluoroaluminates, Al hydroxide, Al sulfate). As for the reasons for the current complacency about Al toxicity to humans from bioavailable sources, some on the other side of the issue have noted that: "Some have argued that I should have been more vocal about the fact that paid consultants for the aluminum industry served as consistent and vocal critics of our findings. I always felt, perhaps naively, that our data were properly collected, honestly and completely reported and were essentially correct. Accordingly, I have felt that the truth would eventually be known and ultimately accepted" [247] . Food for thought?
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